Robust revenues at Gilead, while remdesivir effect is unclear

1 May 2020
gilead-big

Gilead Sciences (Nasdaq: GILD) has reported first quarter 2020 revenues of $5.5 billion, beating analysts’ expectations of around $5.45 billion, an increase of 5% compared with the same period in 2019.

Net income for the first quarter 2020 was $1.6 billion, or $1.22 per share, a decrease of 21%.

The results were driven by a strong performance from the core HIV business, particularly Biktarvy (bictegravir/emtricitabine/tenofovir), with overall revenues of $4.1 billion for the quarter, an increase from $3.6 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology